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Implication for health policy/practice/research/medical education:
A study on 172 live patients receiving hemodialysis indicated that higher age is one of the factors that reduce the effectiveness of 
hepatitis B vaccine in hemodialysis patients.
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Introduction: Hemodialysis patients usually demonstrate lower immune response to hepatitis 
B vaccine compared to non-uremic population.
Objectives: The present study aimed to determine the level of response to hepatitis B 
vaccination in patients under hemodialysis. 
Patients and Methods: This study was conducted on 172 live patients receiving hemodialysis 
in the dialysis department of Buali hospital in Ardabil, Iran (2015). To analyze their response 
to the vaccine, their vaccination titers were investigated. Before vaccination, the serological 
markers of hepatitis B and C were checked in all of the patients. Those for whom HBsAg and 
HBsAb results were negative and had not received the vaccinein the past entered the study. 
The patients received a double dose of hepatitis B vaccine at 0, 1, and 6 months after the 
beginning of dialysis. The response to the vaccine was investigated by measuring the level of 
patients’ hepatitis B antibody one month after receiving the last dose of the vaccine. 
Results: Seventy patients (40% of the total) displayed a proper immune response to the 
vaccine, 34 patients (19.8%) were without, and 68 patients (39.5%) were identified to have poor 
response. The results of Pearson’s correlation test indicated that there is a negative correlation 
between the patients’ age and their response to the vaccine.
Conclusion: The results of this study indicated that higher age is one of the factors that reduce 
the effectiveness of hepatitis B vaccine in hemodialysis patients. 
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Introduction 
Hemodialysis patients are at higher risks of infection 
with hepatitis B virus compared to normal people (1). 
To prevent the spread of this infection in hemodialysis 
patients, the administration of hepatitis B vaccine has 
been recommended. However, the response to the vaccine 
in these patients has been reported to be lower than 
healthy people (2). 
In patients with advanced renal failure, there is a 
suppression of immune system due to uremia which 
results in a decrease in their response to the vaccine (3). 
Various factors have been found to affect the level of 
response to vaccines such as age, gender, nutritional 
status, the duration of dialysis, history of diabetes, dry 
weight, and hepatitis C antibody (4). 
Patients with renal failure who have not yet reached the 
dialysis stage respond better to hepatitis B vaccination 
which shows the relationship between immune response 
and the level of renal failure (5). Various strategies have 
been proposed to increase the immune response to the 
vaccine in these patients. Among them are the addition 
of one extra dose of vaccination (4 doses) or doubling 
the dose of the vaccine (40 µg). The employment of these 
methods has caused the level of seroconversion in patients 
to reach even 80% after taking the vaccine (6). However, 
there are paradoxes in different studies. That is why in 
this study we aimed to investigate the efficacy of double 
dose hepatitis B vaccination and the factors affecting the 
response to it in hemodialysis patients in Ardabil, Iran. 
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Objectives
 The present study aimed to determine the level of response 
to hepatitis B vaccination in patients under hemodialysis. 
Patients and methods
Study population
This study was conducted on all of the patients who were 
receiving hemodialysis maintenance since March 2015 
in the dialysis department of Buali hospital in Ardabil. 
The effect of vaccination on them was investigated with 
reference to their records where in their antibody levels 
were recorded. Before dialysis, antibodies against hepatitis 
B and C were checked in all of the patients. Those for 
whom HBsAg and HBsAb results were negative and had 
not received the vaccine for hepatitis B in the past entered 
to the study. 
To collect information about the patients, a checklist was 
prepared and the information such as name, surname, 
age, gender, and diabetes history, serological profiles 
of hepatitis B, C and also body mass index (BMI) were 
recorded. 
A double dose of hepatitis B vaccine was administered to 
the patients in a 3-dose schedule at 0, 1 and 6 months after 
the beginning of dialysis. The response to the vaccine was 
investigated by measuring the patients’ level of hepatitis 
B antibody one month after receiving the last dose of the 
vaccine. According to their HBsAb antibody level, the 
patients were divided into three groups as follows; 
1. Patients without response (whose antibody levels were 
lower than 10 mIU/mL)
2. Patients with poor response (whose antibody levels 
were in the range of 10-100 mIU/mL)
3. Patients with proper response (whose antibody levels 
were higher than 100 mIU/mL). 
The antibody levels of each patient were recorded in 
their own checklist. Then, at the end of the study, the 
changes in serum HBsAb levels and their relationship 
with demographic factors were investigated. Patients 
who were receiving chemotherapy or consuming 
immunosuppressive drugs were excluded from the study. 
Ethical considerations
This study was conducted following the Declaration 
of Helsinki principles. Informed written consent was 
obtained from each hemodialysis patient. The protocol of 
this study was approved by the Medical Ethics Committee 
of Ardabil University of Medical Sciences with the 
reference code of IR.ARUMS.REC.1394.62. 
Statistical analysis
After collecting the data, they were coded and fed into 
SPSS Software version 19. Data analyzed using the 
inferential statistics of chi-square test, t test, and Pearson’s 
correlation test and reported in figures and tables using 
the descriptive statistical methods. In all instances, the 
significance level was set at 0.05. 
Results 
In this study, 181 hemodialysis patients were selected to be 
studied. Nine of them were excluded because of receiving 
chemotherapy or consuming immunosuppressive drugs. 
As a result, 172 patients remained of whom 98 were male 
and 74 were female. The mean age of the remaining 
patients was 61.19 ± 15.47 years and most of them (45 
patients constituting 26.2% of the total patients) were in 
the age range of 60-70 years. In this study, antibody against 
hepatitis C was not observed in the patients.
The statistical analysis of antibody titers against hepatitis 
B one month after the injection of the last dose of the 
vaccine indicated that 34 patients (19.8%) have titers 
lower than 10 mIU/mL, 68 patients (39.5%) have titers 
in the range of 10-100 mIU/mL, and 70 patients (40.7%) 
have titers higher than 100 mIU/mL (Figure 1). 
Antibody titers were 25.62±4.74 in males and 26.41±3.89 
in females, with no significant difference between two 
genders (P = 0.40). 
On the other hand, the results of Pearson’s correlation test 
indicated a negative correlation between patients’ age and 
the level of titer induced by vaccination (P = 0.001, r = 
-0.37). The negative value of correlation coefficient shows 
Figure 1. The distribution of patients based on the level of antibody titer against hepatitis B 1 month after the injection of the last dose of the 
vaccine.
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that as the patients’ age increases, their level of antibody 
titer decreases. 
The mean body mass index (BMI) of the patients in this 
study was 25.62 ± 4.74 kg/m2. The results of the analysis of 
BMI are presented in Table 1. 
Around 76 patients (44.2%) had diabetes and 32 patients 
(18.66%) were smoker. The results indicated that there is 
no significant relationship between presence of diabetes or 
smoking and the level of response to the vaccine (Table 2). 
Discussion 
The results of the present study revealed no significant 
relationship exists between the patients’ gender and the 
level of antibody titers induced as the result of hepatitis B 
vaccine. Similar to our finding, Navarro et al (4) also did 
not observe a significant relationship between the levels of 
immune titers in male and female hemodialysis patients 
after the injection of hepatitis B vaccine. In some studies, 
the response to the vaccine has been found to be higher in 
females compared to male patients and the concentration 
of anti-HBs antibody produced in females has been 
reported to be three times as much as that produced in 
males (7). 
Pasco et al (8) investigated 111 hemodialysis patients. 
They observed a significant difference between males and 
females in their level of vaccination-induced immunity 
where the level of immunity in females was higher than 
that of males. However, it is not clearly known whether 
this difference in response is due to the difference in the 
body weight of the two genders or their sex hormones. 
In one study, this difference between males and females 
has been attributed to their body weight and it has been 
observed that when it is taken care of, the difference 
between the two groups in their response to vaccination 
no longer exists (9).
Our analysis in this study indicated that the effectiveness of 
vaccination significantly decreases as the age increases and 
older patients show lower response to the vaccine. In line 
with our finding, some studies have reported that patients 
under 40 years of age respond better to vaccination than 
those who are over that age (9). Similarly, Navarro et al (4) 
in their study revealed that as the age increases, the level 
of vaccination-induced immunity against hepatitis B in 
hemodialysis patients decreases. Peces et al (10) injected 
40 µg of the vaccine to patients in a 4-dose schedule. 
They observed proper response in 77.5% of the patients 
72.5% of whom had given a high immune response to the 
vaccination. They reported high response to vaccination 
in 100% of the patients under 40 and 74% of the patients 
over 60 years old. 
In their follow-up of hemodialysis patients, Buti et al 
(11) observed that 41% of the patients lost their anti-HBs 
after 3 years. Those who had preserved their anti-HBs 
were younger and had higher levels of anti-HBs (11). 
This might be related to the decrease in immune system 
strength as the age increase which leads to a poor response 
to vaccination. According to the findings of the present 
study, higher age is one of the factors that affect HBsAb 
titer. It decreases the efficacy of hepatitis B vaccine which 
might be the result of the changes in the immune system 
of the body as people age (12). 
According to the findings of the studies conducted by 
Pasco et al (8), Elwell et al (13), Katedra et al (14) and 
Ebrahim et al (15), no significant relationship was observed 
between the patients’ age, gender, and HCV infection and 
the efficacy of hepatitis B vaccination for them. Moreover, 
Tele et al (16), Roozbeh et al (17) and Daco et al (18) 
indicated no significant relationship between age and the 
level of vaccination-induced immunity against hepatitis B. 
A possible reason for this finding might be the difference 
in the weight and gender of the patients under study. 
The findings of our study demonstrated that there is no 
significant correlation between the patients’ BMI and their 
response to the vaccine. Consistent with our findings, Daco 
et al (18), Tele et al (16), Roozbeh et al (17) and Ebrahim 
et al (15) did not find BMI of hemodialysis patients 
to be an effective factor in their response to hepatitis B 
vaccine. This lack of correlation can be attributed to the 
dependence of response to vaccination to multiple factors. 
In their study, Al Saran et al (12) found that gaining weight 
is a negative factor affecting the level of immunity induced 
as the result of hepatitis B vaccination in hemodialysis 
patients. 
Our findings indicated that smoking and the vaccination-
induced immunity are not significantly related to each 
other. In line with our finding, no significant relationship 
was found between smoking and the level of vaccination-
induced immunity in the study by Al Saran et al (12). 
A possible reason for this finding might be the limited 
number of smokers included in this study.
In some studies, whose findings are inconsistent with 
ours, a decrease has been reported in smokers’ anti-HBs 
response after getting vaccinated with hepatitis B vaccine 
(18,20). The probable mechanism for this result might 
be the effect of smoking on the reduction of immune 
response which, in turn, leads to a lower response to the 
vaccine. 
Table 1. Antibody titer regarding the different BMI levels
Antibody titer
BMI (kg/m2)
<19 25.62±4.74
19-25 25.26±3.44
25-30 24.35±4.52
>30 34.68±3.12
P = 0.35
Table 2. Antibody titer according to diabetes and smoking
Antibody titer P value
Diabetes
Yes 24.65±4.14
0.38
No 25.49±3.28
Smoking
Yes 25.12±3.02
0.45
No 25.88±4.00
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The findings of our study showed no significant 
relationship between having diabetes and the level of 
vaccination-induced immunity. In studies conducted by 
Al Saran et al (12), Daco et al (18), Tele et al (16), Roozbeh 
et al (17), and Peces et al (21), similar findings were 
reported which shows the consistency of our finding with 
them. 
In another study, Fabrizi et al (22) found that the level of 
immunity induced as the result of hepatitis B vaccination 
is lower in hemodialysis patients suffering from diabetes 
compared to those without diabetes. Some of the factors 
that have been found to cause this difference are defective 
cellular immunity in diabetic patients (23), the reduction 
of B-lymphocyte cells and CD4/CD8 ratio of lymphocytes 
(24), and the impaired synthesis of antigens (25). 
In all, the findings of our study indicated that in 
hemodialysis patients, gender, BMI, smoking, and having 
diabetes do not correlate significantly with the response 
to hepatitis B vaccine, while higher age significantly 
decreases its effectiveness.
Conclusion
Higher age was found to be one of the risk factors that 
decrease the efficacy of hepatitis B vaccination in 
hemodialysis patients. Therefore, it is recommended that 
in patients with this risk factor more care be taken and 
more careful follow-ups be conducted over time. 
Limitations of the study
The small proportion of patients included in this study 
was one the limitations of this research.
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